AGIOS PHARMACEUTICALS INC. - COMMON STOCK

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Executive Officer

08 авг 2022 18:36:08 Источник Nasdaq GlobeNewswire

Agios Reports Business Highlights and Second Quarter 2022 Financial Results

04 авг 2022 07:00:02 Источник Nasdaq GlobeNewswire

Agios to Webcast Conference Call of Second Quarter 2022 Financial Results on August 4, 2022

14 июл 2022 07:00:00 Источник Nasdaq GlobeNewswire

Agios Appoints Brian Goff as Chief Executive Officer

12 июл 2022 16:01:00 Источник Nasdaq GlobeNewswire

Agios Presents New Clinical Data Supporting the Benefits of PYRUKYND® (mitapivat) Treatment in Adults with PK Deficiency at European Hematology Association Annual Congress

10 июн 2022 10:30:00 Источник Nasdaq GlobeNewswire

Agios Announces Evolution of Research Organization

16 май 2022 16:15:00 Источник Nasdaq GlobeNewswire

Agios to Present Clinical and Translational Data at the European Hematology Association Annual Congress

12 май 2022 10:00:00 Источник Nasdaq GlobeNewswire

Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 17, 2022

10 май 2022 07:00:05 Источник Nasdaq GlobeNewswire

Agios Reports Business Highlights and First Quarter 2022 Financial Results

05 май 2022 07:00:03 Источник Nasdaq GlobeNewswire

Agios to Webcast Conference Call of First Quarter 2022 Financial Results on May 5, 2022

21 апр 2022 07:00:01 Источник Nasdaq GlobeNewswire

Agios Announces Publication of Phase 3 ACTIVATE Study in New England Journal of Medicine Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency

14 апр 2022 08:34:52 Источник Nasdaq GlobeNewswire

Agios to Participate in March Investor Conferences

28 фев 2022 07:00:01 Источник Nasdaq GlobeNewswire

Agios Reports Fourth Quarter and Full Year 2021 Financial Results

24 фев 2022 07:00:03 Источник Nasdaq GlobeNewswire

Agios Announces FDA Approval of PYRUKYND® (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency

17 фев 2022 15:41:11 Источник Nasdaq GlobeNewswire

Agios to Webcast Conference Call of Fourth Quarter and Year End 2021 Financial Results on Feb. 24, 2022

10 фев 2022 07:00:01 Источник Nasdaq GlobeNewswire

Agios Highlights 2022 Anticipated Milestones and Priorities to Drive Company’s Strategic Vision in Genetically Defined Diseases

10 янв 2022 07:00:02 Источник Nasdaq GlobeNewswire

Agios to Present at 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022

22 дек 2021 07:00:00 Источник Nasdaq GlobeNewswire

Agios Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Burden Reduction in Adults with Pyruvate Kinase (PK) Deficiency at 63rd ASH Annual Meeting and Exposition

13 дек 2021 18:15:00 Источник Nasdaq GlobeNewswire

Agios Presents Mitapivat Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis in Non-transfusion-dependent α- and β-Thalassemia at 63rd ASH Annual Meeting and Exposition

13 дек 2021 10:30:00 Источник Nasdaq GlobeNewswire

Agios Announces Data from Investigator-led Studies of Mitapivat in Adults with Sickle Cell Disease Demonstrating Improvements in Anemia, Hemolysis and Sickling Parameters at 63rd ASH Annual Meeting and Exposition

13 дек 2021 07:00:01 Источник Nasdaq GlobeNewswire